

PTQ/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Please do not display a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to provide information unless it is requested by a person in the official capacity of a Federal agency and the collection of information is necessary for the proper performance of the official duties of that agency.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Application Number	10/720,323
Filing Date	November 24, 2003
First Named Inventor	Jill Giles-Komar
Group Art Unit	1644
Examiner Name	
Attorney Docket Number	CEN 249 CIPNP

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ²
		Office ³	Number ⁴	KindCode ⁵				
mt	B1	WO	0031248	A	Smithkline Beecham Corp.	08-02-2000		
mt	B2	WO	0044404	A	Children's Hospital	08-03-2000		
mt	B3	WO	95/25543	A1	Scripps Research Institute	09-28-1995		
mt	B4	WO	97/06791	A1	Scripps Research Institute	02-27-1997		
mt	B5	WO	97/36859	A1	G. D. Searle & Co.	10-09-1997		
mt	B6	WO	93/20229	A1	Genentech, Inc.	10-14-1993		
mt	B7	EPO	719859	A1	Merck Patent GMBH	07-03-1996		

Examiner
Signature

Maher Haddad

Date
Considered

1/27/06

Examiner Signature	Mohr Haddad	Date Considered	1/21/06
-----------------------	-------------	--------------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, which is not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Time will vary depending upon the needs of the individual case. A mark Office

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(attach as necessary)

(use as many sheets as necessary)

Sheet 2 of 3

U.S. PATENT DOCUMENTS

Application Number	10/720,323
Filing Date	November 24, 2003
First Named Inventor	Jill Giles-Komar
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN 249 CIPNP

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature <u>Maher Haddad</u>	Date Considered <u>1/27/06</u>
--	--------------------------------

Examiner Signature	Maher Haddad	Date Considered	1/21/88
--------------------	--------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference consulted with next communication to applicant.
considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

7 To complete. Time will vary depending upon the needs of the individual case. A
8 Trademark Office

number of the patent document. * Kind of document by its appropriate code (WFO). * If English language Translation is attached, possible. * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.



(use as many sheets as necessary)

Sheet 3 of 3

PTQ/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
This document displays a valid OMB control number.

Application Number	10/720,323
Filing Date	November 24, 2003
First Named Inventor	Jill Giles-Komar
Group Art Unit	1644
Examiner Name	
Attorney Docket Number	CEN 249 CIPNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			T ²
Examiner's Initials*	Cite No.†	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
mH		TAM et al, "Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and $\alpha_5\beta_3$ Integrins," vol. 98, No. 11, 09-15-1998, pages 1098-1091, USA	
mH		TRIKHA et al, "A potential new application for a cardiovascular drug: Role for ReoPro (Abciximab), an inhibitor of GPIIb/IIIa and $\alpha_5\beta_3$ integrins, as an anti-cancer agent," Proceedings of the American Association for Cancer Research, vol. 41, March 2000, page 577, USA.	
mH		SUZUKI et al, "cDNA and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin reveal a transmembrane domain and homologies with other adhesion protein receptors," Cell Biology, November 1986, pages 8614-8618, vol. 83, Proc. National Academy Science, USA.	
mH		LEHMANN ET AL, "A monoclonal antibody inhibits adhesion to fibronectin and vitronectin of a colon carcinoma cell line and recognizes the integrins $\alpha_5\beta_3$, $\alpha_5\beta_1$, $\alpha_5\beta_2$," Cancer Research, 1994, pages 2102-2107, Vol. 54, USA.	
mH		GUNTHER CASTL, THOMAS HERMANN, MCIAHEL STEURER, JORG ZMJA, EBERHARD GUNSILIUS, CLEMENS UNGER, AND ANDREA KRAFT, "Angiogenesis as a target for tumor treatment," Oncology, 1997, 177-84, Vol. 54.	
mH		BRIAN P. EUCEIRI AND DAVID A. CHERESH, "The role of $\alpha_5\beta_1$ integrins during angiogenesis: insights into potential mechanisms of action and clinical development," The Journal of Clinical Investigation, May 1999, 1227-30, vol. 103, no. 9.	
mH		MARTIN FRIEDLANDER, PETER C. BROOKS, ROBERT W. SHAFFER, CHRISTINE M. KINCAID, JUDITH A. VARNER, AND DAVID A. CHERESH, "DEFINITION OF TWO ANGIOGENIC PATHWAYS BY DISTINCT ALPHA-V INTEGRINS," Science, Dec. 1, 1995, 1500-2, vol. 270.	
mH		LISA D. TAYLOR, CONDIE E. CARMACK, DENNIS HUSZAR, KAY M. HIGGINS, ROSHANAK MASHAYEKH, GETACHEW SEQUAR, STEPHEN R. SCHRAMM, CHIUNG-CHI KUO, SUSAN L. O'DONNELL, ROBERT M. KAY, OLIVE S. WOODHOUSE, AND NILS LONBERG, "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM," International Immunology, 1994; 579-91, vol. 6 no. 4, Oxford University Press.	
mH		NILS LONBERG, USA D. TAYLOR, FIONA A. HARDING, MARY TROUNSTINE, KAY M. HIGGINS, STEPHEN R. SCHRAMM, CHIUNG-CHI KUO, ROSHANAK MASHAYEKH, KATHRYN WYMORE, JAMES G. MCCABE, DONNA MUNOZ-O'REGAN, SUSAN L. O'DONNELL, ELIZABETH S. G. LAPACHET, TASH BENGEOECHEA, DIANNE M. FISHWILD, CONDIE E. CARMACK, ROBERT M. KAY AND DENNIS HUSZAR, "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," Nature, April 28, 1994, 856-9, vol. 368.	
mH		MICHAEL NEUBERGER, "Generating high-avidity human Mabs in mice," Nature Biotechnology, July 1996, 826, vol. 14.	
mH		DIANNE M. FISHWILD, SUSAN L. O'DONNELL, TASH BENGEOECHEA, DEBRA V. HUDSON, FIONA HARDING, SUSAN L. BERNHARD, DEBBIE JONES, ROBERT M. KAY, KAY M. HIGGINS, STEPHEN R. SCHRAMM, AND NILS LONBERG, "High-avidity human IgG-kappa monoclonal antibodies from a novel strain of minilocus transgenic mice," Nature Biotechnology, July 1996, 845-51, vol. 14.	
mH		ELIZABETH A. WAYNER, ROBERT A. ORLANDO AND DAVID A. CHERESH, "Integrins $\alpha_5\beta_1$ and $\alpha_5\beta_3$ and $\alpha_5\beta_1$ contribute to Cell Attachment to Vitronectin but Differentially Distribute on the Cell Surface," J. Cell Biology, May 1991, 919-29, vol. 113, no. 4.	
mH		JOHN F. MARSHALL, DEBORAH C. RUTHERFORD, ALISON C.E. MCCARTNEY, FRANCESC MITJANS, SIMON L. GOODMAN AND IAN R. HART, "Alpha v beta 1 is a receptor for vitronectin and fibrinogen, and acts with alpha 5 beta 1 to mediate spreading on fibronectin," J. of Cell Science, 1995, 1227-38, vol. 108.	
mH		DAVID A. CHERESH AND ROBERT C. SPIRO, "Biosynthetic and Functional Properties of an Arg-Gly-Asp-directed Receptor Involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen, and von Willebrand Factor," J. of Biological Chemistry, Dec. 25 1987, 17703-11, vol. 262, no. 38.	
mH		HANS KEMPERMAN, YVONNE M. WUNANDS, AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells: Adhesion to Fibronectin is Mediated Solely by Small Amounts of alpha v beta 6, and alpha v beta 5 is Codistributed with Actin Fibers," Experimental Cell Research, 1997, 156-64, vol. 234.	
mH		MAXIME LEHMANN, CHANTAL BABENANDRASANA, RICHARD TAMUBA, JEAN-CLAUDE USSITZKY, VITO GUARANTA, JACQUES PICHON, AND JACQUES MARVALDI, "A Monoclonal Antibody Inhibits Adhesion to Fibronectin and Vitronectin of a Colon Carcinoma Cell Line and Recognizes the Integrins $\alpha_5\beta_1$, $\alpha_5\beta_3$, $\alpha_5\beta_2$, and $\alpha_5\beta_4$," Cancer Research, Apr 15 1994, 2102-07, vol. 54.	

Sheet 1 of 1 FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: July 12, 2004		ATTY DOCKET NO. 2002_1351 APPLICANT Yukio TOYODA et al. FILING DATE October 15, 2002	SERIAL NO. 10/270,323 In 726,323 GROUP 1641
---	--	---	---

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	AA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
mt	AJ	0 260 829	3/1988	EP	X	X		
mt	AK	0 834 557	4/1998	EP				
	AL							
	AM							
	AN							

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

mt	AO	J. Orihara, "Sensitizing Capacity, Cross-Reactivity and Antigenic Determinants of Bisphenol A", The Journal of Stomatological Society, Vol. 59, No. 2, June 1992, pp. 439-455. <i>English Abstract only.</i>
mt	AP	M. Castillo et al., "Analysis of Industrial Effluents to Determine Endocrine-Disrupting Chemicals", Trends in Analytical Chemistry, Vol. 16, No. 10, November 12, 1997, pp. 574- 583.
mt	AQ	J. Gascon et al., "Detection of Endocrine-Disrupting Pesticides by Enzyme-Linked Immunosorbent Assay (ELISA): Application to Atrazine", Trends in Analytical Chemistry, Vol. 16, No. 10, 1997, pp. 554-562.

EXAMINER <i>Maher Haddad</i>	DATE CONSIDERED <i>1/27/06</i>
------------------------------	--------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of form with next communication to applicant.



SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	10/720,323
Filing Date	NOVEMBER 24, 2003
First Named Inventor	JILL GILES-KOMAR
Group Art Unit	1644
Examiner Name	
Attorney Docket Number	CEN249CIPNP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	U.S. Patent Document		Pages, Columns, Lines, where relevant passages or relevant figures appear
			Number	Kind Code ² (if known)	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Foreign Patent Document			Pages, Columns, Lines, where relevant passages or relevant figures appear	T ²
			Office ³	Number ⁴	Kind Code ⁵		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials [*]	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MT		MITJANS et al, "In Vivo Therapy of Malignant Melanoma by Means of Antagonists of α v Integrins," Int. J. Cancer, 2000, pp 716-723, Vol. 87, Wiley-Liss, Inc., Spain.	
MT		MITJANS et al, "An anti- α v-Integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice," Journal of Cell Science, 1995, pp 2825-2838, Vol. 108, The Company of Biologists Limited, Great Britain.	
MT		CASEL et al, "RGD Peptides and Monoclonal Antibodies, Antagonists of α -Integrin, Enter the Cells by Independent Endocytic Pathways," Laboratory Investigation, 2001, pp 1615-1626, Vol. 81, No. 12, The United States and Canadian Academy of Pathology, Inc., USA.	

Examiner Signature	Maher Haddad	Date Considered	1/27/06
--------------------	--------------	-----------------	---------